Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Mar 9:13:18.
doi: 10.1186/s12958-015-0014-3.

Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old

Massimo Tartagni  1 , Maria V Cicinelli  2 , Domenico Baldini  3 , Mario V Tartagni  4 , Hala Alrasheed  5 , Maria A DeSalvia  6 , Giuseppe Loverro  7 , Monica Montagnani  8
Affiliations
Randomized Controlled Trial

Dehydroepiandrosterone decreases the age-related decline of the in vitro fertilization outcome in women younger than 40 years old

Massimo Tartagni et al. Reprod Biol Endocrinol. .

Abstract

Background: With infertility populations rapidly aging, treatments improving pregnancy chances assume increasing clinical importance. Dehydroepiandrosterone (DHEA) has been reported to improve pregnancy rates and lower miscarriage rates in women with diminished ovarian function. This study was planned to evaluate whether pretreatment with DHEA may improve in vitro fertilization (IVF) parameters and pregnancy outcomes in infertile women with advanced reproductive age and normal ovarian reserve.

Methods: In this double-blind, randomized, placebo-controlled study, 109 infertile patients aging 36-40 years old were selected to undergo the long protocol IVF. Eight weeks before starting the IVF cycle and during treatment, patients in Group 1 received 75 mg of DHEA once a day; patients in control group (Group 2) received placebo. The primary endpoint of the study was number of clinical pregnancy, live birth and miscarriage rates; secondary endpoint was modification of standard IVF parameters, including stimulation duration (days of rhFSH administration), E2 on HCG-day, endometrial thickness, number of retrieved oocytes, metaphase II oocytes, number of transferred embryos and score of leading embryos transferred.

Results: Patients in the DHEA group had a significantly higher live birth rate compared with controls (P<0.05). Conversely, miscarriage rate was higher for patients in the control group (P<0.05).

Conclusions: DHEA supplementation may significantly improve IVF outcomes in infertile women with advanced reproductive age and normal ovarian reserve.

PubMed Disclaimer

References

    1. Cabry R, Merviel P, Hazout A, Belloc S, Dalleac A, Copin H, et al. Management of infertility in women over 40. Maturitas. 2014;78:17–21. doi: 10.1016/j.maturitas.2014.02.014. - DOI - PubMed
    1. Arlt W. Dehydroepiandrosterone and ageing. Best Pract Res Clin Endocrinol Metab. 2004;18:363–80. doi: 10.1016/j.beem.2004.02.006. - DOI - PubMed
    1. Yakin K, Urman B. DHEA as a miracle drug in the treatment of poor responders; hype or hope? Hum Reprod. 2011;26:1941–4. doi: 10.1093/humrep/der150. - DOI - PubMed
    1. Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet. 2007;24:629–34. doi: 10.1007/s10815-007-9178-x. - DOI - PMC - PubMed
    1. Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod. 2006;21:2845–9. doi: 10.1093/humrep/del254. - DOI - PubMed

Publication types

Substances

LinkOut - more resources